PRNewswire

Dakota Hotels Emerges as Premier Example of Enhanced Guest Experience through Collaborative Technology Deployment

HOFFMAN ESTATES, Ill., June 4, 2024 /PRNewswire/ -- Cambium Networks (NASDAQ: CMBM), a leading global provider of networking solutions, today announced its collaboration with Nonius, a leading global company offering digital technology for hotel guests. This strategic partnership leverages Cambium Networks' advanced hospitality solutions which include... (continue reading...)

NEW YORK, June 4, 2024 /PRNewswire/ -- MFG Partners ("MFG"), a New York-based private equity firm focused on investing in closely held lower-middle market industrial companies, announces the first and final close of its inaugural private equity fund ("Fund I"). Fund I was oversubscribed and secured $299,180,000 in total commitments from a diverse set of institutional investors comprised of university endowments, insurance companies, pension funds, and private... (continue reading...)

HONG KONG and SHANGHAI, June 4, 2024 /PRNewswire/ -- China's macroeconomy and capital market development remains steady this year, and Ping An will maintain a balanced "double barbell" asset allocation to ensure stable returns, said Benjamin Deng, Chief Investment Officer of Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An", the "Company" or the "Group", HKEX: 2318 / 82318; SSE: 601318). Mr. Deng was speaking at Asian Investor's Asian Investment... (continue reading...)

Two new studies demonstrate how aerogels could provide cooling to buildings and protection from harmful electromagnetic waves emitted by electronic devices

SINGAPORE, June 4, 2024 /PRNewswire/ -- Aerogels, known for their porosity and low density, are solid materials that offer versatile functionality — from gobbling up fat globules in weight-management supplements to facilitating more sustainable metal-recycling processes. Traditionally used to provide thermal... (continue reading...)

• This regulatory milestone marks an acceleration of the process around NT-I7's potential first indication, after other recent positive news.
• NeoImmuneTech's NT-I7 has shown potential in nonclinical studies to address the immunosuppressive effects of ARS.

ROCKVILLE, Md.  , June 4, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announced that the European Medicines Agency (EMA) has... (continue reading...)